ASCO 2026 Poster Presentation: A multicenter, randomized, double-blind, phase 2/3 study of ficerafusp alfa (BCA101) or placebo in combination with pembrolizumab for first-line treatment of PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: FORTIFI-HN01
Saturday, May 30, 2026 BiopharmaWatch Research 1 min read
Key Takeaway: The ASCO 2026 presentation discusses a phase 2/3 study evaluating ficerafusp alfa (BCA101) combined with pembrolizumab for treating PD-L1-positive recurrent or metastatic head and neck squamous cell carcinoma. This multicenter, randomized, double-blind trial aims to assess the efficacy of this treatment approach. The study represents a significant advancement in cancer therapy.
Price reaction · baseline $21.75 (2026-05-29 close) · clean, no other BCAX news in the window
day 0 close
-5.2%
day 1 · peak
-9.7%
day 3
-6.2%
Market Sentiment Analysis
POSITIVE FACTORS
The study is a multicenter, randomized, double-blind trial.
It focuses on a novel treatment combination for a challenging cancer type.
The presentation at ASCO 2026 highlights significant research efforts.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+36%
120-day peak, hindsight
Typical move
12.1%
average across 2 past catalysts
Cash runway
~33 mo
Minimal dilution risk
Lead asset
Ficerafusp alfa
Phase 2 · Squamous Cell Carcinoma of Head and Neck (SCCHN)
Full Press Release Details
The post ASCO 2026 Poster Presentation: A multicenter, randomized, double-blind, phase 2/3 study of ficerafusp alfa (BCA101) or placebo in combination with pembrolizumab for first-line treatment of PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: FORTIFI-HN01 appeared first on Bicara Therapeutics .
Frequently Asked Questions
What is the focus of the FORTIFI-HN01 study?
The study focuses on ficerafusp alfa combined with pembrolizumab for treating PD-L1-positive head and neck cancer.
What type of study is FORTIFI-HN01?
It is a multicenter, randomized, double-blind, phase 2/3 study.
Where was the FORTIFI-HN01 study presented?
The study was presented at ASCO 2026.
What type of cancer is being targeted in this study?
The study targets recurrent or metastatic head and neck squamous cell carcinoma.